EE03746B1 - Farmatseutiline kompositsioon tsüklooksügenaas-2 vahendatud haiguste raviks, 3-fenüül-4-(4-(metüülsulfonüül) fenüül)-2-(5H)-furanooni kasutamine ja ühikuline oraalne doseerimisvorm - Google Patents

Farmatseutiline kompositsioon tsüklooksügenaas-2 vahendatud haiguste raviks, 3-fenüül-4-(4-(metüülsulfonüül) fenüül)-2-(5H)-furanooni kasutamine ja ühikuline oraalne doseerimisvorm

Info

Publication number
EE03746B1
EE03746B1 EE9800393A EE9800393A EE03746B1 EE 03746 B1 EE03746 B1 EE 03746B1 EE 9800393 A EE9800393 A EE 9800393A EE 9800393 A EE9800393 A EE 9800393A EE 03746 B1 EE03746 B1 EE 03746B1
Authority
EE
Estonia
Prior art keywords
phenyl
furanone
cyclooxygenase
methylsulfonyl
treatment
Prior art date
Application number
EE9800393A
Other languages
English (en)
Estonian (et)
Other versions
EE9800393A (et
Inventor
Hancock Bruno
Winters Conrad
Gertz Barry
Ehrich Elliot
Original Assignee
Merck & Co., Inc.
Merck Frosst Canada & Co. / Merck Frosst Canada &Cie.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26309472&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE03746(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9612063.9A external-priority patent/GB9612063D0/en
Application filed by Merck & Co., Inc., Merck Frosst Canada & Co. / Merck Frosst Canada &Cie. filed Critical Merck & Co., Inc.
Publication of EE9800393A publication Critical patent/EE9800393A/xx
Publication of EE03746B1 publication Critical patent/EE03746B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EE9800393A 1996-05-17 1997-05-13 Farmatseutiline kompositsioon tsüklooksügenaas-2 vahendatud haiguste raviks, 3-fenüül-4-(4-(metüülsulfonüül) fenüül)-2-(5H)-furanooni kasutamine ja ühikuline oraalne doseerimisvorm EE03746B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1787896P 1996-05-17 1996-05-17
GBGB9612063.9A GB9612063D0 (en) 1996-06-10 1996-06-10 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
PCT/US1997/008041 WO1997044028A1 (en) 1996-05-17 1997-05-13 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases

Publications (2)

Publication Number Publication Date
EE9800393A EE9800393A (et) 1999-06-15
EE03746B1 true EE03746B1 (et) 2002-06-17

Family

ID=26309472

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800393A EE03746B1 (et) 1996-05-17 1997-05-13 Farmatseutiline kompositsioon tsüklooksügenaas-2 vahendatud haiguste raviks, 3-fenüül-4-(4-(metüülsulfonüül) fenüül)-2-(5H)-furanooni kasutamine ja ühikuline oraalne doseerimisvorm

Country Status (29)

Country Link
US (1) US6063811A (cs)
EP (1) EP0910368A1 (cs)
JP (1) JPH11512754A (cs)
KR (1) KR100373622B1 (cs)
CN (1) CN1140267C (cs)
AR (1) AR012014A1 (cs)
AU (1) AU3004997A (cs)
BG (1) BG103000A (cs)
BR (1) BR9709097A (cs)
CA (1) CA2254061C (cs)
CO (1) CO5050370A1 (cs)
CZ (1) CZ291463B6 (cs)
DZ (1) DZ2200A1 (cs)
EA (1) EA001596B1 (cs)
EE (1) EE03746B1 (cs)
HK (1) HK1021623A1 (cs)
HR (1) HRP970262A2 (cs)
HU (1) HUP9902889A3 (cs)
ID (1) ID16921A (cs)
IL (1) IL126899A (cs)
IS (1) IS4891A (cs)
MY (1) MY116201A (cs)
NO (1) NO985342L (cs)
NZ (1) NZ332670A (cs)
PE (1) PE66998A1 (cs)
PL (1) PL188649B1 (cs)
SK (1) SK284330B6 (cs)
TR (1) TR199802345T2 (cs)
WO (1) WO1997044028A1 (cs)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
CA2322824A1 (en) * 1998-03-13 1999-09-16 Merck & Co., Inc. Combination therapy and composition for acute coronary ischemic syndrome and related conditions
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
CO5190664A1 (es) 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
GB9920558D0 (en) * 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
AU2731401A (en) * 1999-12-22 2001-07-03 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
US6924303B2 (en) 2000-06-13 2005-08-02 Wyeth Analgesic and anti-inflammatory compositions containing COX-2 inhibitors
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
ES2265439T3 (es) * 2000-08-18 2007-02-16 Pharmacia Corporation Formulacion oral de valdecoxib que se desintegra rapidamente.
US8680081B2 (en) * 2000-08-29 2014-03-25 Peter Van Patten Prophylactic treatment of migraine
PE20020351A1 (es) * 2000-09-11 2002-06-14 Novartis Ag Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US20040132780A1 (en) * 2001-05-04 2004-07-08 Allen Christopher P. Method and compositions for treating migraines
AR036312A1 (es) * 2001-08-31 2004-08-25 Novartis Ag Composicion farmaceutica
KR20040058189A (ko) * 2001-09-26 2004-07-03 파마시아 코포레이션 관능상 허용가능한 경구내 붕해 조성물
MXPA04003404A (es) * 2001-10-10 2004-06-18 Pharmacia Corp Composiciones de valdecoxib de disgregacion intraoral preparadas mediante un procedimiento de desecacion por pulverizacion.
CN1330300C (zh) * 2002-03-07 2007-08-08 诺瓦提斯公司 药物组合物
ES2213485B1 (es) 2003-02-13 2005-12-16 Almirall Prodesfarma, S.A. Derivados de la 2-fenilpiran-4-ona.
ES2214129B1 (es) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 3-fenilfuran-2-onas.
DE602004002832T2 (de) 2003-05-07 2007-06-06 Osteologix A/S Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
TR200301552A1 (tr) * 2003-09-18 2005-10-21 Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. Rofekoksib' in yeni oral farmakolojik formülasyonları.
WO2008091530A2 (en) * 2007-01-19 2008-07-31 Mallinckrodt Inc. Diagnostic and therapeutic cyclooxygenase-2 binding ligands
KR20210124188A (ko) 2018-11-21 2021-10-14 트루모 파마슈티칼스, 인크. 정제된 형태의 로페콕시브, 제조 및 사용 방법
US20200323830A1 (en) * 2019-04-09 2020-10-15 Tremeau Pharmaceuticals, Inc. Treatment of viral hemorrhagic fevers with etoricoxib
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
SG43841A1 (en) * 1994-01-10 1997-11-14 Merck Frosst Canada Inc Phenyl heterocycles as cox-2 inhibitors

Also Published As

Publication number Publication date
NO985342D0 (no) 1998-11-16
KR20000011082A (ko) 2000-02-25
CZ291463B6 (cs) 2003-03-12
AU3004997A (en) 1997-12-09
BR9709097A (pt) 1999-08-03
CA2254061C (en) 2003-12-02
DZ2200A1 (fr) 2004-06-20
TR199802345T2 (xx) 1999-03-22
EE9800393A (et) 1999-06-15
SK156798A3 (en) 2000-01-18
IL126899A0 (en) 1999-09-22
WO1997044028A1 (en) 1997-11-27
NZ332670A (en) 2000-07-28
PE66998A1 (es) 1998-10-24
AR012014A1 (es) 2000-09-27
CO5050370A1 (es) 2001-06-27
IL126899A (en) 2004-03-28
EA001596B1 (ru) 2001-06-25
SK284330B6 (sk) 2005-01-03
CZ373898A3 (cs) 1999-06-16
MY116201A (en) 2003-11-28
KR100373622B1 (ko) 2003-07-12
BG103000A (en) 1999-09-30
EA199801017A1 (ru) 1999-04-29
EP0910368A1 (en) 1999-04-28
CN1140267C (zh) 2004-03-03
HUP9902889A3 (en) 2002-04-29
CN1225010A (zh) 1999-08-04
US6063811A (en) 2000-05-16
HRP970262A2 (en) 1998-06-30
HUP9902889A2 (hu) 2002-01-28
HK1021623A1 (en) 2000-06-23
PL329940A1 (en) 1999-04-26
JPH11512754A (ja) 1999-11-02
NO985342L (no) 1998-11-16
IS4891A (is) 1998-11-10
CA2254061A1 (en) 1997-11-27
PL188649B1 (pl) 2005-03-31
ID16921A (id) 1997-11-20

Similar Documents

Publication Publication Date Title
EE03746B1 (et) Farmatseutiline kompositsioon tsüklooksügenaas-2 vahendatud haiguste raviks, 3-fenüül-4-(4-(metüülsulfonüül) fenüül)-2-(5H)-furanooni kasutamine ja ühikuline oraalne doseerimisvorm
EE03969B1 (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
BR9711194A (pt) Uso de agente quelante clioquinol para a fabricação de uma composição farmacêutica para o tratamento de doença de alzheimer.
DE69225421D1 (de) Sumatriptan enthaltende Arzneimittel
BR0107565A (pt) Formas de dosagem de benzimidazol substituìdo e método de emprego das mesmas
EE9600118A (et) Uus peroraalne farmatseutiline annusvorm
EE200000395A (et) Peroraalne farmatseutiline pulseeriva vabanemisega annusvorm
NO963568D0 (no) Farmasöytisk preparat for behandling av blodkoagulasjonssykdommer, fremgangsmåter for fremstilling av dette og dets anvendelse
PT1083879E (pt) Metodos e dispositivos para proporcionar uma terapia de drogas prolongada
BRPI9908182B8 (pt) composições de proteína de matriz para cura de feridas
IL178072A (en) Use of monoesters of probucol or a pharmaceutically acceptable salt thereof for preparing medicaments for the treatment of cardiovascular and inflammatory disease
EE04997B1 (et) Loteprednooli ja antihistamiinseid aineid sisaldav farmatseutiline kompositsioon, neid aineid sisaldav ravim, meetod selle ravimi valmistamiseks ja nende ainete kombinatsiooni kasutamine
EE9700014A (et) Uus peroraalne ravimvorm, mis sisaldab omeprasooli magneesiumsoola
SE9700885D0 (sv) New pharmaceutical formulation
EE04493B1 (et) Tsüklopenteeni derivaadid, neid sisaldav farmatseutiline kompositsioon ning ühendite kasutamine ravimina inimestel esinevate motiliini retseptoriga seotud häirete raviks
MX9708803A (es) Compuestos biaromaticos de propinilo o dienilo.
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
BR9913982A (pt) Derivado de piridil-4h-1,2,4-oxadiazina opticamente ativo e seu uso no tratamento de doenças vasculares
PT1150681E (pt) Utilizacao de uma composicao farmaceutica que contem desoxipeganina para o tratamento da dependencia da nicotina
AR006281A1 (es) Utilizacion de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4- piperidinometanol o sus sales de adicion de acidos farmaceuticamenteaceptables en el tratamineto de trastornos depresivos y trastornos bipolares
HUP0001104A2 (hu) Ibuprofent és domperidont tartalmazó készítmények migrén kezelésére
AU8015398A (en) Pharmaceutical formulations containing colostrum and the use of colostrum for the treatment of affections of the oral cavity
EE200200551A (et) Oligosahhariide sisaldav farmatseutiline kompositsioon, oligosahhariidid, nende valmistamine ja raviotstarbeline kasutamine
EE03514B1 (et) Ühendite kombinatsioon HIV infektsiooni või AIDS-i raviks, selle kasutamine ja farmatseutiline kompositsioon
HUP0402092A3 (en) Use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts for preparation of pharmaceutical compositions

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20120513